secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056482
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31
--------------------------------------------------------------------------------

- Offering of 19.73M shares at $17.75/share plus 1.4M pre-funded warrants at $17.749/warrant.
- Underwriters exercised overallotment option for 3.17M additional shares in full on May 6.
- Net proceeds estimated at $405M; proceeds to fund clinical development of abdakibart through Phase 3 topline data.
- Preliminary cash, cash equivalents and short-term investments as of March 31, 2026: $82.0M.
- Expected closing May 7, 2026; cash runway expected to extend into 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer